Company press release


Clinical trial commenced

Kiel, 11/24/2005 – The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), the German Federal Institute for pharmaceuticals and medical products, has notified Proteo Biotech AG of allowance to commence Phase I clinical trials. It is the first clinical trial on individuals involving the active agent Elafin, an elastase and proteinase 3-inhibitor. The Institut für Klinische Pharmakologie at Kiel, an experienced Contract Research Organization, has been engaged to perform the study. Currently, in close cooperation with Proteo Biotech AG Elafin is tested on 32 healthy individuals. It is aimed to evaluate tolerability, safety, pharmacokinetic and dynamics of Elafin. First results are expected before the year’s end.


Barbara Kahlke, Ph.D.
Proteo Biotech AG
Am Kiel-Kanal 44
D-24106 Kiel

Telephone: +49 431 8888-462
Fax: +49 431 8888-463 – printed on 2020-09-23 8:20:03